Zenas BioPharma Launches As A Cross-border Biopharma Company

Zenas BioPharma has launched a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. Zenas aims for rapid advancement in its current portfolio and to establish its global leadership with an expanded pipeline coupled with a strong footprint in China. Zenas was founded and initially funded by Tellus BioVentures, LLC and Fairmount Funds Management LLC and is additionally backed by a syndicate of leading global life science investment funds including Quan Capital, WuXi Biologics Healthcare Ventures and Wellington Management. Lonnie Moulder, Executive Chairman and Interim Chief Executive Officer at Zenas says, “We are excited about the launch of Zenas BioPharma and its pipeline of differentiated product candidates. These potentially best-in-class products are intended to bring innovation to patients with underserved diagnoses while also maximizing value across the healthcare ecosystem,” said Mr. Moulder. “The expanding Zenas leadership team and our network of business partners will drive operational excellence to deliver potentially transformative therapies to improve the lives of people living with autoimmune and rare diseases.” Zenas debuts with a deep pipeline of seven innovative immune-based therapeutics that will continue to expand through a successful business development strategy. Zenas owns worldwide rights to three of the seven pipeline programs, which uniquely positions the Company to be global in scope. Zenas innovation is defined by the selection of product candidates that are designed with best-in-class potential and then advanced utilizing differentiated development and commercial strategies to address patient needs AND the value requirements of the dynamic healthcare environment.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!